FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304080778> ?p ?o ?g. }

• W4304080778 endingPage "e064338" @default.
• W4304080778 startingPage "e064338" @default.
• W4304080778 abstract "Psoriatic arthritis (PsA) is a chronic, inflammatory, musculoskeletal disease that affects up to 30% of patients with psoriasis. Current challenges in clinical care and research include personalised treatment, understanding the divergence of therapy response and unravelling the multifactorial pathophysiology of this complex disease. Moreover, there is an urgent clinical need to predict, assess and understand the cellular and molecular pathways underlying the response to disease-modifying antirheumatic drugs (DMARDs). The TOFA-PREDICT clinical trial addresses this need. Our primary objective is to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in PsA.In this investigator-initiated, phase III, multicentre, open-label, four-arm randomised controlled trial, we plan to integrate clinical, molecular and imaging parameters of 160 patients with PsA. DMARD-naïve patients are randomised to methotrexate or tofacitinib. Additionally, patients who are non-responsive to conventional synthetic (cs)DMARDs continue their current csDMARD and are randomised to etanercept or tofacitinib. This results in four arms each with 40 patients. Patients are followed for 1 year. Treatment response is defined as minimal disease activity at week 16. Clinical data, biosamples and images are collected at baseline, 4 weeks and 16 weeks; at treatment failure (treatment switch) and 52 weeks. For the first 80 patients, we will use a systems medicine approach to assess multiomics biomarkers and develop a prediction model for treatment response. Subsequently, data from the second 80 patients will be used for validation.The study was approved by the Medical Research Ethics Committee in Utrecht, Netherlands, is registered in the European Clinical Trials Database and is carried out in accordance with the Declaration of Helsinki. The study's progress is monitored by Julius Clinical, a science-driven contract research organisation.EudraCT: 2017-003900-28." @default.
• W4304080778 created "2022-10-10" @default.
• W4304080778 creator A5000137571 @default.
• W4304080778 creator A5001050128 @default.
• W4304080778 creator A5004200111 @default.
• W4304080778 creator A5013844633 @default.
• W4304080778 creator A5017043157 @default.
• W4304080778 creator A5038553975 @default.
• W4304080778 creator A5039255500 @default.
• W4304080778 creator A5041143781 @default.
• W4304080778 creator A5042588935 @default.
• W4304080778 creator A5050305173 @default.
• W4304080778 creator A5071278144 @default.
• W4304080778 creator A5071908846 @default.
• W4304080778 creator A5073704317 @default.
• W4304080778 creator A5079495785 @default.
• W4304080778 creator A5084902406 @default.
• W4304080778 date "2022-10-01" @default.
• W4304080778 modified "2023-09-27" @default.
• W4304080778 title "TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA)" @default.
• W4304080778 cites W1679485188 @default.
• W4304080778 cites W2029510325 @default.
• W4304080778 cites W2033299724 @default.
• W4304080778 cites W2036407878 @default.
• W4304080778 cites W2066943555 @default.
• W4304080778 cites W2067902190 @default.
• W4304080778 cites W2068573602 @default.
• W4304080778 cites W2071376363 @default.
• W4304080778 cites W2079920967 @default.
• W4304080778 cites W2083180635 @default.
• W4304080778 cites W2086325363 @default.
• W4304080778 cites W2096991001 @default.
• W4304080778 cites W2113717019 @default.
• W4304080778 cites W2129597937 @default.
• W4304080778 cites W2130111449 @default.
• W4304080778 cites W2130454548 @default.
• W4304080778 cites W2133432325 @default.
• W4304080778 cites W2133701923 @default.
• W4304080778 cites W2140760073 @default.
• W4304080778 cites W2151628746 @default.
• W4304080778 cites W2153836018 @default.
• W4304080778 cites W2157118376 @default.
• W4304080778 cites W2163183022 @default.
• W4304080778 cites W2163387772 @default.
• W4304080778 cites W2170800858 @default.
• W4304080778 cites W2171250984 @default.
• W4304080778 cites W2223868808 @default.
• W4304080778 cites W2271197668 @default.
• W4304080778 cites W2290571943 @default.
• W4304080778 cites W2313513962 @default.
• W4304080778 cites W2555024914 @default.
• W4304080778 cites W2592793178 @default.
• W4304080778 cites W2625583840 @default.
• W4304080778 cites W2734610919 @default.
• W4304080778 cites W2770103135 @default.
• W4304080778 cites W2770642598 @default.
• W4304080778 cites W2795500234 @default.
• W4304080778 cites W2805359702 @default.
• W4304080778 cites W2806678383 @default.
• W4304080778 cites W2806806917 @default.
• W4304080778 cites W2894871910 @default.
• W4304080778 cites W2897926336 @default.
• W4304080778 cites W2898481649 @default.
• W4304080778 cites W2911460674 @default.
• W4304080778 cites W2911505485 @default.
• W4304080778 cites W2933294150 @default.
• W4304080778 cites W2942189803 @default.
• W4304080778 cites W2967237728 @default.
• W4304080778 cites W2975383698 @default.
• W4304080778 cites W3022896986 @default.
• W4304080778 cites W3025818142 @default.
• W4304080778 cites W3027539208 @default.
• W4304080778 cites W3081535908 @default.
• W4304080778 cites W3083830923 @default.
• W4304080778 cites W3094570888 @default.
• W4304080778 cites W4241915332 @default.
• W4304080778 cites W4283589104 @default.
• W4304080778 doi "https://doi.org/10.1136/bmjopen-2022-064338" @default.
• W4304080778 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36216430" @default.
• W4304080778 hasPublicationYear "2022" @default.
• W4304080778 type Work @default.
• W4304080778 citedByCount "0" @default.
• W4304080778 crossrefType "journal-article" @default.
• W4304080778 hasAuthorship W4304080778A5000137571 @default.
• W4304080778 hasAuthorship W4304080778A5001050128 @default.
• W4304080778 hasAuthorship W4304080778A5004200111 @default.
• W4304080778 hasAuthorship W4304080778A5013844633 @default.
• W4304080778 hasAuthorship W4304080778A5017043157 @default.
• W4304080778 hasAuthorship W4304080778A5038553975 @default.
• W4304080778 hasAuthorship W4304080778A5039255500 @default.
• W4304080778 hasAuthorship W4304080778A5041143781 @default.
• W4304080778 hasAuthorship W4304080778A5042588935 @default.
• W4304080778 hasAuthorship W4304080778A5050305173 @default.
• W4304080778 hasAuthorship W4304080778A5071278144 @default.
• W4304080778 hasAuthorship W4304080778A5071908846 @default.
• W4304080778 hasAuthorship W4304080778A5073704317 @default.
• W4304080778 hasAuthorship W4304080778A5079495785 @default.
• W4304080778 hasAuthorship W4304080778A5084902406 @default.

• next